Oppenheimer Starts Celgene (CELG) at Outperform

November 28, 2016 4:05 PM EST
Get Alerts CELG Hot Sheet
Price: $117.63 -1.04%

Rating Summary:
    28 Buy, 8 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 11 | Down: 31 | New: 42
Trade CELG Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Oppenheimer initiates coverage on Celgene (NASDAQ: CELG) with a Outperform rating and a price target of $141.00.

Analyst Leah Rush Cann commented, "We are initiating coverage of Celgene Corporation, a high-quality biotechnology company with exciting potential new products, with an Outperform rating. We estimate Celgene’s revenue will grow at a compound annual growth rate of 19% per year for the next five years, with product growth of 19.2% per year. Diluted GAAP earnings per share are estimated to grow at a CAGR of 31% over the next five years."

For an analyst ratings summary and ratings history on Celgene click here. For more ratings news on Celgene click here.

Shares of Celgene closed at $121.06 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Hot New Coverage, New Coverage

Related Entities

Earnings

Add Your Comment